GO Therapeutics is pioneering the development of advanced cancer therapies by focusing on the identification of super-clean tumor targets. These targets are unique to tumor cells and are not present on healthy cells, addressing a significant limitation in current cancer treatments that often lead to toxic side effects due to the targeting of antigens found on both tumors and normal tissues. By utilizing truncated O-glycans, which are sugar-based molecules specific to various carcinomas, GO Therapeutics aims to enhance the safety and efficacy of therapies such as bispecific T-cell antibodies, antibody-drug conjugates (ADCs), and CAR-T cells. Their innovative approach involves a proprietary platform that combines glycobiology, clinical data, and bioinformatics to discover and develop high-affinity antibodies against these tumor-specific antigens.

The company has established a robust pipeline of products targeting multiple solid tumors, including breast cancer and other high-unmet-need indications. Each therapeutic candidate is paired with a companion diagnostic that accurately identifies patients likely to respond to treatment, thereby optimizing therapeutic outcomes. GO Therapeutics is committed to providing more tolerable and effective treatment options, moving away from traditional toxic therapies and towards a future where patients can benefit from targeted, low-toxicity cancer treatments. This strategic focus on super-clean targets not only aims to improve patient safety but also seeks to expand the applicability of advanced cancer therapies to a broader patient population.

United States

GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors.

We target O-linked glycoproteins specific to cancer cells to develop proprietary, high-affinity antibodies to novel cancer-specific targets. Our antibodies are the basis for a broad array of potent cancer-killing modalities including T-cell bispecifics (TCBs), CAR-T, and antibody drug conjugates (ADCs). Each are designed to kill cancer while sparing healthy tissue.

GO Therapeutics

Company Details